Dry Eye 2020

More documents

Info

DRY EYE 2020 New point-of-care test for dry eye By A/Prof Laura Downie ACCURATE AND EARLY diagnosis of dry eye disease is currently a clinical challenge, as many current tests are invasive, time-consuming and inaccurate¹. Dry eye disease affects about one in five adults and is a common indication for medical eye care in developed countries². The condition adversely affects the tear film and ocular surface, potentially leading to eye pain, impaired vision and reduced qualityof-life. Clinicians have access to a broad range of therapies³ but need to know which to use and when to use them. It is of critical importance to determine the main subtype of dry eye (ie. evaporative or aqueousdeficient), as this informs treatment decisions⁴. However, currently there is no single method to both diagnose and subtype dry eye disease. The research programme at the Anterior Eye, Clinical Trials and Research Translation Unit in the Department of Optometry and Vision Sciences at the University of Melbourne, integrates laboratory, clinical and implementation science to support the translation of discovery research into practice. Over the past three years, one of our major projects has focused on the development of a new point-ofcare test for rapid and accurate dry eye diagnosis and subtyping. The technology is known as ADMiER, acoustically driven microfluidic extensional rheometry, and involves analysing the viscoelastic (stretching) properties of a small tear droplet. It is the first application of microfluidic extensional rheometry for ophthalmic diagnostics. The ability to both diagnose and subtype dry eye disease using ADMiER, in a single analytical step, makes the approach a transformative advance over current tests. The intended users of this technology are optometrists and ophthalmologists. Translation of the device into eye care practice is predicted to benefit eye care clinicians and the healthcare system by improving practice efficiency through faster, more accurate and cost-effective patient triaging. For dry eye patients, the diagnostic and subtyping information provided by the technology will be able to directly inform treatment, so that dry eye management protocols are optimised. In the long-term, this has the capacity to drive improvements in patient health outcomes. I am currently leading the commercial development of the technology, in collaboration with Professor Leslie Yeo and Dr Amarin McDonnell from RMIT University, Melbourne. To date, we have built a research-grade prototype of the device, secured a strong patent portfolio and published an initial clinical dataset that demonstrates ADMiER’s diagnostic utility⁵. Since 2019, our team has presented the technology at several prestigious scientific meetings and pitched to local potential investors. Our team was recently awarded a National Health and Medical Research Council (NHMRC) development grant to support further development and commercialisation of the technology. This next stage of development focuses on undertaking a body of research relating to clinical validation of the device and developing and optimising a next-generation prototype. We are working towards the ADMiER product being available on the market within the next five years. A/Prof Laura Downie References 1. Downie LE, Keller PR, Vingrys AJ. An evidence-based analysis of Australian optometrists’ dry eye practices. Optom Vis Sci 2013;90(12):1385-95. 2. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf 2017;15(3):334-65. 3. Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf 2017;15(3):575- 628. 4. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf 2017;15(3):539-74. 5. McDonnell A, Lee JH, Makrai E, et al. Tear Film Extensional Viscosity Is a Novel Potential Biomarker of Dry Eye Disease. Ophthalmology 2019. Associate Professor Laura Downie heads up the Anterior Eye, Clinical Trials and Research Translation Unit in the Department of Optometry and Vision Sciences at the University of Melbourne. She is a sought-after international speaker, has published many papers and served on several national and international expert panels, standards committees and industry advisory boards, and is an editorial board member on several scientific journals, including Ophthalmology. Xiidra pulled NOVARTIS HAS SHELVED Xiidra in Europe after the European Medicines Agency (EMA) said its effectiveness in treating dry eye disease (DED) had not been demonstrated effectively. Novartis bought the DED prescription eye drop from Takeda Pharmaceutical last year for US$5.3 billion, including $3.4 billion upfront and $1.9 billion in milestone payments, three years after the drop was approved by the US Food and Drug Administration (FDA). “Although some effect was seen in the reduction of eye dryness, the improvement was not considered clinically significant,” said the EMA, noting there was also no long-term data on Xiidra despite DED being a chronic disease. The clinical data for Xiidra was further criticised for only being compared with a placebo, rather than other eye drop treatments. Novartis confirmed it was voluntarily withdrawing its European marketing application as, “the majority of objections raised cannot be resolved within the available time frame.” It reserved the right to make further submissions in the future but confirmed there were currently no ongoing trials for Xiidra. 30 | NEW ZEALAND OPTICS SEPTEMBER 2020
“DRY EYE CLINIC” START YOURS TODAY Be passionate ANTARES • TOPOGRAPHY + ABERROMETRY MAPS • FULL DRY EYE REPORT • CONTACT LENSES FITTING • KERATOCONUS SCREENING & FOLLOW UPS • PUPILLOGRAPHY • VIDEO NBUT • IR MEIBOGRAPHY • AUTO FOCUS TECHNOLOGY • HD VIDEOS + PHOTOS REXON-EYE • PLEASANT • LONG LASTING RELIEF • AFFORDABLE • ALL FORMS OF DED • NO ONGOING COST • SAFE SESSIONS SCREENING ALL patients (3min) Pre & Post surgery (cataract/refractive) DIAGNOSTIC Evaluate All DED parameters Open a discussion about DED management / Or not, with patient PATIENTS EDUCATION Dry eye report is accurate & “Theatrical” for patients to understand DED and the importance of the treatment TREATMENT 4 Sessions 20 Minutes each 1 Week interval FOLLOW UPS Monitoring of the ocular surface improvements Scan & Watch EYETEK Pty Ltd 1300 618 336 excellent@eyetek.com.au Scan & Watch WWW.EYEONOPTICS.CO.NZ | 31
Page 1 and 2: and present… Dry Eye 2020 l AI fo
Page 3 and 4: Seeing more with the first digital
Page 5 and 6: Simo Zhang, Karyn Zhao, Dr Andy Kim
Page 8 and 9: DRY EYE 2020 OSL: The benefits of b
Page 10 and 11: DRY EYE 2020 OSL: Blink tracking 2.
Page 12 and 13: DRY EYE 2020 ECPs’ approach to dr
Page 14 and 15: Meibomian Gland Dysfunction (MGD),
Page 16 and 17: DRY EYE 2020 Preserved or non-prese
Page 18 and 19: Preservative-free FULLY FUNDED NOVA
Page 22 and 23: DRY EYE 2020 DED and immune-mediate
Page 24 and 25: EYE ON OPHTHALMOLOGY Castor oil for
Page 26 and 27: DRY EYE 2020 Continued from p35 Ack
Page 28 and 29: Visit eyeonoptics.co.nz or eyeonopt
Page 30 and 31: DRY EYE 2020 When should you check
Page 32 and 33: FOCUS ON EYE RESEARCH Dr Mo Ziaei,

Dry Eye 2020

Create successful ePaper yourself

Delete template?

Save as template?